CCL2 and coronary artery disorder: As shown in Figure 2, in vitro treatment of PBMC from Asy and CHD patients with 100 μM fenofibrate, reduces the levels of IL-12, TGF-β, IL-6, MCP1 in comparison with untreated cells (Figures 2A–D, F–I).